Strategic Acquisition PLUS Diagnostics was recently acquired by Miraca Life Sciences, signaling potential integration opportunities for expanded service offerings, shared resources, and cross-sell of pathology services to MLS’s broader client base.

Service breadth As a CLIA-certified lab with specialties in genitourinary, gastrointestinal, dermatopathology, hematopathology, breast, and oral/maxillofacial pathology, PLUS has a wide pathology service portfolio that can be bundled or tailored for hospital systems seeking end-to-end diagnostic solutions.

Growth potential Revenue in the mid single to lower double digits with 51–200 employees indicates a nimble, growth-oriented mid-market player that can scale partnerships, reference labs programs, or regional expansion initiatives with health systems and large clinics.

Quality differentiator Accreditations from CAP and CLIA certification, along with a reputation for precision, offer a compelling value proposition for hospitals pursuing high-quality diagnostic benchmarks and standardized pathology workflows.

Market positioning Position PLUS as a specialized, high-precision pathology partner to mid-size health networks and regional health systems, highlighting capabilities to complement larger labs and fill gaps in subspecialty pathology coverage.